Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of GeneDx Holdings Corp (NASDAQ: WGS) was $108.08 for the day, down -1.10% from the previous closing price of $109.28. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 0.7 million shares were traded. WGS stock price reached its highest trading level at $113.23 during the session, while it also had its lowest trading level at $106.71.
Ratios:
Our analysis of WGS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 201.94. For the most recent quarter (mrq), Quick Ratio is recorded 2.59 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Buy rating and assigned the stock a target price of $155.
On July 09, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.Guggenheim initiated its Buy rating on May 15, 2025, with a $88 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 16 ’25 when Feeley Kevin sold 3,855 shares for $143.87 per share. The transaction valued at 554,616 led to the insider holds 8,731 shares of the business.
Stueland Katherine sold 10,857 shares of WGS for $1,562,185 on Dec 16 ’25. The CHIEF EXECUTIVE OFFICER now owns 14,237 shares after completing the transaction at $143.89 per share. On Dec 09 ’25, another insider, Feeley Kevin, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 1,266 shares for $159.28 each. As a result, the insider received 201,648 and left with 5,389 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 3124008192 and an Enterprise Value of 3082089984. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1792.37, and their Forward P/E ratio for the next fiscal year is 240.12. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.77 while its Price-to-Book (P/B) ratio in mrq is 10.68. Its current Enterprise Value per Revenue stands at 7.663 whereas that against EBITDA is 88.916.
Stock Price History:
The Beta on a monthly basis for WGS is 2.10, which has changed by 0.45346963 over the last 52 weeks, in comparison to a change of 0.14725316 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $170.87, while it has fallen to a 52-week low of $55.17. The 50-Day Moving Average of the stock is -22.95%, while the 200-Day Moving Average is calculated to be -1.29%.
Shares Statistics:
WGS traded an average of 536.38K shares per day over the past three months and 757590 shares per day over the past ten days. A total of 28.89M shares are outstanding, with a floating share count of 25.35M. Insiders hold about 12.28% of the company’s shares, while institutions hold 104.53% stake in the company. Shares short for WGS as of 1767139200 were 3072640 with a Short Ratio of 5.73, compared to 1764288000 on 3594043. Therefore, it implies a Short% of Shares Outstanding of 3072640 and a Short% of Float of 21.180001.
Earnings Estimates
Its stock is currently analyzed by 7.0 different market analysts. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.06 and low estimates of -$0.13.
Analysts are recommending an EPS of between $1.44 and $1.29 for the fiscal current year, implying an average EPS of $1.37. EPS for the following year is $0.38, with 4.0 analysts recommending between $0.67 and $0.05.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $122.1M to a low estimate of $119.2M. The current estimate, GeneDx Holdings Corp’s year-ago sales were $95.64MFor the next quarter, 8 analysts are estimating revenue of $117.5M. There is a high estimate of $119.6M for the next quarter, whereas the lowest estimate is $115.4M.
A total of 9 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $428.7M, while the lowest revenue estimate was $425.7M, resulting in an average revenue estimate of $427.04M. In the same quarter a year ago, actual revenue was $305.45MBased on 4 analysts’ estimates, the company’s revenue will be $538.6M in the next fiscal year. The high estimate is $545.6M and the low estimate is $532.2M.
